Project Grant R44DK126579
Award Date
9/5/24
Completion Date
7/31/26
Dollars Obligated
$1M
Awardee
Elixera, Inc. (VVAPLHY7JAD7)
Federal Grant Program
93.847
Assistance Type
Project Grant
Place of Performance
Redwood City, CA 94063, USA
Similar Awards
This $929,940 Project Grant awarded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under CFDA Program 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research supports the development of a novel dual agonist biologic drug candidate to safely treat type I and type II diabetics experiencing impaired awareness of hypoglycemia (IAH). The project aims to pursue manufacturing, formulation, efficacy validation, and safety studies on 3 lead candidates over a...
The U.S. Department of Health and Human Services' National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $361,400 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to Oncotrap Inc. The funding supports the development of a bispecific single-domain antibody targeting the chemokines CCL2 and CCL5 for the treatment of non-alcoholic steatohepatitis (NASH). The award will enable Oncotrap to generate a human version...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $538,354 to support research on the role of the hypothalamic ADGRL1 receptor in mediating the counterregulatory response to hypoglycemia. The 5-year project, scheduled to run from June 2025 to March 2030, aims to establish the contribution of ADGRL1 in the ventromedial nucleus of the...
This Project Grant award, valued at $1,726,182.00, was issued by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award aims to explore new protein kinase A (PKA) mutants that locally drive cortisol secretion in adrenal Cushing's syndrome, an endocrine disorder where adrenal cells release excess stress hormone cortisol. The research will evaluate the mutational...
This $1,145,486 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under CFDA 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research supports the development of novel peripherally acting CB1 neutral antagonist compounds for treating diabetic kidney disease (DKD). The funding will enable Makscientific LLC, a for-profit R&D company, to design, synthesize, and evaluate analogs of the lead compound AM6588 with improved...
This Project Grant award in the amount of $553,545.00 was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award will support research conducted by The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to elucidate the mechanisms by which methylation of the GNAS gene regulates allelic expression of the stimulatory G...
This federal Project Grant award in the amount of $1,428,186 was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award supports research to investigate the role of CYP4F enzymes in regulating N-acyl amino acid signaling in humans, and the impact of this biochemical interaction on cellular metabolism and downstream biomarkers of cardiometabolic disease. The...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) supports the development of a long-acting parathyroid hormone (PTH) derivative, EXT608, for the treatment of hypoparathyroidism. The $999,615 award to Extend Biosciences Inc., a woman-owned small business, will fund a Phase 2 clinical trial to evaluate the safety, tolerability, and efficacy of...
The National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases awarded $3.6 million under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to Anagram Therapeutics Inc. to develop a novel pancreatic enzyme replacement therapy. Specifically, Anagram will engineer lipase enzymes for improved stability against low pH and proteolytic degradation. This will allow for effective digestion of fats in both the stomach and small...
This federal Project Grant award for $1,902,420 was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award will support research to investigate the molecular mechanisms underlying pituitary cell plasticity and adaptability in response to changing hormonal demands. The project aims to determine the role of post-transcriptional regulation, specifically the...